CVD, Metabolic Disease, Dupilumab Efficacy in COPD
Summary of Dupilumab Study in COPD Patients with Comorbidities
This article reports on a poster presentation at the European Respiratory Society International Congress regarding the efficacy and safety of dupilumab in COPD patients, specifically looking at how it performs in those with and without cardiovascular disease (CVD) and metabolic disease.
Key Findings:
* Exacerbation Reduction: Dupilumab significantly reduced moderate to severe COPD exacerbations to a similar degree in patients with and without CVD (-31% vs.-33%) and with and without metabolic disease (-32% vs. -31%).
* FEV1 Improvement: Dupilumab led to comparable improvements in pre-bronchodilator FEV1 (a measure of lung function) regardless of CVD or metabolic disease history. Improvements were +55mL with CVD and +104mL without CVD, and +62mL with metabolic disease and +77mL without metabolic disease.
* Safety: The safety profile of dupilumab was consistent – there was no important difference in the rate of treatment-emergent adverse events (including serious events) between patients with and without CVD or metabolic disease.
* Overall Assessment: Dr. John Hurst, quoted in the article, characterized the results as ”vital and reassuring,” highlighting the importance of maintaining efficacy in higher-risk patient populations.
In essence, the study suggests that dupilumab is effective and safe for COPD patients even if they also have common comorbidities like cardiovascular or metabolic disease.
Further Information:
* The data comes from the BOREAS and NOTUS clinical trials.
* Further subgroup analysis from these trials is planned.
* Dr. John Hurst can be contacted at j.hurst@ucl.ac.uk.